Insulin Degludec facilitates a prolonged duration of action through a distinct subcutaneous depot mechanism:

• Post-Injection Self-Association: Unlike rapid-acting monomers, Degludec exists as stable di-hexamers in the presence of phenol and zinc. Upon injection, phenol dissipates, triggering the formation of long, soluble multi-hexamer chains at the injection site.
•  
• Sequestration and Slow Dissociation: Zinc ions slowly dissociate from these multi-hexamers, resulting in a continuous, gradual release of Degludec monomers into the circulation, ensuring a peakless pharmacokinetic profile.
•  
• Reversible Albumin Binding: The fatty acid side chain enables the molecule to bind reversibly to serum albumin, further retarding systemic clearance and extending the biological half-life to approximately 25 hours.

• Basal Insulin Therapy: Ideal for U-100 and U-200 high-concentration formulations, allowing for lower injection volumes and improved patient adherence.
•  
• Combination Regimens: Suitable for developing fixed-ratio combinations with rapid-acting insulins (e.g., Insulin Aspart) to provide both basal and prandial coverage.
•  
• Biosimilar Consistency: High-purity crystalline powder optimized for analytical comparability studies, ensuring bioequivalence to the reference medicinal product (RMP).

Unlike Insulin Glargine, which relies on pH-dependent precipitation, Insulin Degludec utilizes a soluble multi-hexamer mechanism. This results in significantly lower within-subject variability and a flatter glucose-lowering effect, making it the preferred API for reducing nocturnal hypoglycemia risk in basal insulin regimens.

How do you manage the risk of fatty acid side-chain oxidation during synthesis?

The acylation of LysB29 is a critical process step. Xi'an Tihealth employs high-precision acylation technology and validated HPLC-MS to monitor the stability of the 16-carbon fatty diacid side chain. We ensure every batch is nitrogen-sealed to prevent oxidative degradation, preserving the biological potency for formulation.

Can Xi'an Tihealth provide analytical support for biosimilarity (IND/NDA) filings?

Yes. We provide complete technical packages including secondary and tertiary structural characterization (via Circular Dichroism and MS-mapping). Our quality team assists biosimilar developers with the necessary documentation for regulatory audits and Drug Master File (DMF) Letter of Access (LOA).

What are the validated cold-chain protocols for international air freight?

We recognize that peptide stability is non-negotiable. We utilize isothermal shipping containers with temperature loggers to maintain a strict -20°C environment. We coordinate with premium air-freight handlers to ensure zero-risk transit from Xi'an to your manufacturing facility, mitigating any fibrillation risk.

Is your recombinant yeast process free from animal-derived raw materials?

Absolutely. Our Insulin Degludec is 100% Non-Animal Origin (NAO). We provide formal TSE/BSE-free statements and non-GMO certifications for every batch, simplifying the quality risk assessment and simplifying regulatory compliance for clinical-grade production.